(Q37777010)

23 August 2017

1 reference

title

Prediabetes: the importance of early identification and intervention (English)

1 reference

23 August 2017

Prediabetes: The Importance of Early Identification and Intervention (English)

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

14 June 2024

author name string

Laurie Orloski

2

1 reference

23 August 2017

Kathleen Wyne

3

1 reference

23 August 2017

Willa A. Hsueh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20675976

14 June 2024

language of work or name

English

0 references

publication date

1 July 2010

1 reference

full work available at URL

23 August 2017

http://www.tandfonline.com/doi/pdf/10.3810/pgm.2010.07.2180

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

14 June 2024

published in

Postgraduate Medicine

1 reference

23 August 2017

volume

122

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

129-143

1 reference

Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Diabetes and ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Diabetic neuropathies: clinical manifestations and current treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Normal fasting plasma glucose levels and type 2 diabetes in young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Predicting the 20-year diabetes incidence rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Neuropathy associated with prediabetes: what is new in 2007?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Impaired glucose tolerance and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Prevalence and 15-year incidence of retinopathy and associated characteristics in middle-aged and elderly diabetic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Is there a clear threshold for fasting plasma glucose that differentiates between those with and without neuropathy and chronic kidney disease?: the Singapore Prospective Study Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Is microalbuminuria part of the prediabetic state? The Mexico City Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes in the Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

IGT with fasting hyperglycemia is more strongly associated with microalbuminuria than IGT without fasting hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Prediabetes: a must to recognise disease state

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Integration of metabolism and inflammation by lipid-activated nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Minireview: Adiposity, Inflammation, and Atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Endocrine functions of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Insulin sensitivity: modulation by nutrients and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Fatty acid oxidation and insulin action: when less is more

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Mode of onset of type 2 diabetes from normal or impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Predictors of future fasting and 2-h post-OGTT plasma glucose levels in middle-aged men and women-the Inter99 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Coronary vasomotor abnormalities in insulin-resistant individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Fetuin-A induces cytokine expression and suppresses adiponectin production

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Fetuin-A and incident diabetes mellitus in older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

The underlying mechanisms for development of hypertension in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Identification and treatment of prediabetes to prevent progression to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Tool to assess likelihood of fasting glucose impairment (TAG-IT).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Is prevention of Type-2 diabetes feasible and efficient in primary care? A systematic PubMed review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Cardiovascular prevention in patients with diabetes and prediabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Impact of different topical negative pressure levels on myocardial microvascular blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Cardiovascular manifestations of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

The prevention of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Exercise and cardiovascular risk reduction: time to update the rationale for exercise?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

One-year weight losses in the Look AHEAD study: factors associated with success

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

How effective are lifestyle changes in the prevention of type 2 diabetes mellitus?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

(How) can we prevent type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Anti-diabetic effect of blockade of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Effect of valsartan on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Navigating the choices for diabetes prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Rationale and strategies for early detection and management of diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Subclinical states of glucose intolerance and risk of death in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Cognitive function and health-related quality of life in elderly patients with hypertension--baseline data from the study on cognition and prognosis in the elderly (SCOPE).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2180

Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes

21 January 2018

19

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

Diabetic neuropathy in older adults

14 June 2024

21

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

Microalbuminuria precedes the development of NIDDM

14 June 2024

33

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: a cross-sectional analytic study

14 June 2024

35

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes

14 June 2024

66

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians

14 June 2024

72

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

Co-expression of renin-angiotensin system genes in human adipose tissue

14 June 2024

80

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

Insulin resistance and hypertension

14 June 2024

82

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study

14 June 2024

129

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

Captopril prevention project--what shall we do about captopril and the risk of stroke?

14 June 2024

135

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

14 June 2024

137

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2180

14 June 2024

Identifiers

1 reference

23 August 2017

1 reference